Press "Enter" to skip to content

New patent for Boehringer Ingelheim drug GLYXAMBI

0
Copyright © DrugPatentWatch. Originally published at New patent for Boehringer Ingelheim drug GLYXAMBI

Annual Drug Patent Expirations for GLYXAMBI
Annual Drug Patent Expirations for GLYXAMBI

Glyxambi is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are thirteen patents protecting this drug and one Paragraph IV challenge.

GLYXAMBI drug price trends.

Drug patent litigation for GLYXAMBI.

This drug has four hundred and twenty-three patent family members in forty-six countries.

The generic ingredient in GLYXAMBI is empagliflozin; linagliptin. One supplier is listed for this compound. Additional details are available on the empagliflozin; linagliptin profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Copyright © DrugPatentWatch. Originally published at New patent for Boehringer Ingelheim drug GLYXAMBI
    Do NOT follow this link or you will be banned from the site!